Watson Pharmaceuticals Inc. is rolling out Amethia Lo tablets, an oral contraceptive.


Watson Pharmaceuticals, Amethia Lo, levonorgestrel/ethinyl estradiol, ethinyl estradiol, LoSeasonique, generic equivalent, Teva Women's Health, oral contraceptive, generic market exclusivity, prevention of pregnancy




























































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Watson introduces Amethia Lo

December 8th, 2011

PARSIPPANY, N.J. – Watson Pharmaceuticals Inc. is rolling out Amethia Lo tablets, an oral contraceptive.

Watson said late Wednesday that it has launched Amethia Lo (levonorgestrel/ethinyl estradiol 0.1 mg/0.02 mg) and ethinyl estradiol (0.01 mg) tablets under a settlement with Teva Women's Health Inc.

The product is a generic equivalent of Teva's LoSeasonique, indicated for the prevention of pregnancy.

Terms of the agreement weren't disclosed. Watson said that as a first applicant to submit a substantially complete abbreviated new drug application (ANDA), it's eligible for 180 days of shared generic market exclusivity.

For the 12 months ended Sept. 30, LoSeasonique had sales of about $28 million, according to IMS Health figures reported by Watson.

Advertisement